Brown Advisory’s Regulus Therapeutics RGLS Stock Holding History

Brown Advisory’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-288	Closed	-$114K	–	1151
2016 Q3	$114K	Hold	288	–	–	﹤0.01%	1038
2016 Q2	$100K	Hold	288	–	–	﹤0.01%	1016
2016 Q1	$239K	Sell	288 -1	-0.3%	-$796	﹤0.01%	884
2015 Q4	$303K	Buy	289 +1	+0.3%	+$1K	﹤0.01%	796
2015 Q3	$226K	Buy	+288	New	+$296K	﹤0.01%	857

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SDIC

South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Brown Advisory's RGLS Position: Q4 2016 in Review

Brown Advisory sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 288 shares — an estimated $114K sold.

Brown Advisory first reported a position in RGLS in Q3 2015 and held it in 5 quarters. The position peaked at $303K in Q4 2015. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

Brown Advisory reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
Brown Advisory sold 288 Regulus Therapeutics shares in Q4 2016, an estimated $114K.
Brown Advisory first reported a position in Regulus Therapeutics in Q3 2015 and held it in 5 quarters.
Brown Advisory's Regulus Therapeutics position peaked at $303K in Q4 2015.
68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Brown Advisory's 13F filing for Q4 2016, filed 13 Feb 2017.